News | November 10, 2023
Aurobindo Pharma posts Q2 FY 24 up 84% at Rs. 752 Cr
The company reported net profit after share of profit/loss of JV and minority interest at Rs. 752 crore vs. Rs. 409 crore in Q2FY23
The company reported net profit after share of profit/loss of JV and minority interest at Rs. 752 crore vs. Rs. 409 crore in Q2FY23
New Molecular biology lab launched, AIIA increased its work scope in form of MoUs
Ayush Minister launched month long ayurveda celebration drive of Ministry of Ayush
The introduction of 'Definisse Core Filler' is a testament to the company's premium scientific-based innovation
Sun Pharma is granted rights for marketing Sovateltide in India under the brand name Tyvalzi (Sovateltide)
The brand has launched 6 new range of products to provide a complete pregnancy care solution
Need to harmonize traditional and modern medicine to combat alarming health problems
Aurobindo's product is already filed with the Drugs Controller General of India (DCGI) and is expected to be approved soon
Especially valuable for young patients with multiple blocks & underlying conditions that may render angioplasty procedures with drug-eluting stents ineffective
With close to 30-40 basic screening tests available, the unit encompasses all the essential parameters typically covered in annual health check-ups
Subscribe To Our Newsletter & Stay Updated
